Literature DB >> 27217707

Chinese physicians' perceptions of fecal microbiota transplantation.

Rong-Rong Ren1, Gang Sun1, Yun-Sheng Yang1, Li-Hua Peng1, Shu-Fang Wang1, Xiao-Hong Shi1, Jing-Quan Zhao1, Yong-Ling Ban1, Fei Pan1, Xue-Hong Wang1, Wei Lu1, Jian-Lin Ren1, Ying Song1, Jiang-Bin Wang1, Qi-Ming Lu1, Wen-Yuan Bai1, Xiao-Ping Wu1, Zi-Kai Wang1, Xiao-Mei Zhang1, Ye Chen1.   

Abstract

AIM: To explore Chinese physicians' perceptions towards fecal microbiota transplantation (FMT) and to provide information and an assessment of FMT development in China.
METHODS: A self-administered questionnaire was developed according to the FMT practice guidelines and was distributed to physicians in hospitals via Internet Research Electronic Data Capture (REDcap) software and electronic mails to assess their attitudes toward and knowledge of FMT. The questionnaire included a brief introduction of FMT that was followed by 20 questions. The participants were required to respond voluntarily, under the condition of anonymity and without compensation. Except for the fill-in-the-blank questions, all of the other questions were required in the REDcap data collection systems, and the emailed questionnaires were completed based on eligibility.
RESULTS: Up to December 9, 2014, 844 eligible questionnaires were received out of the 980 distributed questionnaires, with a response rate of 86.1%. Among the participants, 87.3% were from tertiary hospitals, and there were 647 (76.7%) gastroenterologists and 197 (23.3%) physicians in other departments (non-gastroenterologists). Gastroenterologists' awareness of FMT prior to the survey was much higher than non-gastroenterologists' (54.3 vs 16.5%, P < 0.001); however, acceptance of FMT was not statistically different (92.4 vs 87.1%, P = 0.1603). Major concerns of FMT included the following: acceptability to patients (79.2%), absence of guidelines (56.9%), and administration and ethics (46.5%). On the basis of understanding, the FMT indications preferred by physicians were recurrent Clostridium difficile infection (86.7%), inflammatory bowel disease combined with Clostridium difficile infection (78.6%), refractory ulcerative colitis (70.9%), ulcerative colitis (65.4%), Crohn's disease (59.4%), chronic constipation (43.7%), irritable bowel syndrome (39.1%), obesity (28.1%) and type 2 diabetes (23.9%). For donor selection, the majority of physicians preferred individuals with a similar gut flora environment to the recipients. 76.6% of physicians chose lower gastrointestinal tract as the administration approach. 69.2% of physicians considered FMT a safe treatment.
CONCLUSION: Chinese physicians have awareness and a high acceptance of FMT, especially gastroenterologists, which provides the grounds and conditions for the development of this novel treatment in China. Physicians' greatest concerns were patient acceptability and absence of guidelines.

Entities:  

Keywords:  Chinese physicians; Fecal microbiota transplantation; Gastroenterologists; Perception; Survey

Mesh:

Year:  2016        PMID: 27217707      PMCID: PMC4870082          DOI: 10.3748/wjg.v22.i19.4757

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.

Authors:  B EISEMAN; W SILEN; G S BASCOM; A J KAUVAR
Journal:  Surgery       Date:  1958-11       Impact factor: 3.982

2.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.

Authors:  Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp
Journal:  Gastroenterology       Date:  2012-06-20       Impact factor: 22.682

Review 3.  Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.

Authors:  Ethan Gough; Henna Shaikh; Amee R Manges
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

4.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

5.  Markers for transfusion-transmitted disease in different groups of blood donors.

Authors:  J M Starkey; J L MacPherson; D C Bolgiano; E R Simon; T F Zuck; M H Sayers
Journal:  JAMA       Date:  1989 Dec 22-29       Impact factor: 56.272

6.  Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.

Authors:  Lawrence J Brandt; Olga C Aroniadis; Mark Mellow; Amy Kanatzar; Colleen Kelly; Tina Park; Neil Stollman; Faith Rohlke; Christina Surawicz
Journal:  Am J Gastroenterol       Date:  2012-03-27       Impact factor: 10.864

Review 7.  Treating Clostridium difficile infection with fecal microbiota transplantation.

Authors:  Johan S Bakken; Thomas Borody; Lawrence J Brandt; Joel V Brill; Daniel C Demarco; Marc Alaric Franzos; Colleen Kelly; Alexander Khoruts; Thomas Louie; Lawrence P Martinelli; Thomas A Moore; George Russell; Christina Surawicz
Journal:  Clin Gastroenterol Hepatol       Date:  2011-08-24       Impact factor: 11.382

Review 8.  The human microbiome: at the interface of health and disease.

Authors:  Ilseung Cho; Martin J Blaser
Journal:  Nat Rev Genet       Date:  2012-03-13       Impact factor: 53.242

9.  [A pilot study of treating ulcerative colitis with fecal microbiota transplantation].

Authors:  Rongrong Ren; Gang Sun; Yunsheng Yang; Lihua Peng; Xiuli Zhang; Shufang Wang; Yan Dou; Xiaomei Zhang; Zikai Wang; Xiaochen Bo; Qingsen Liu; Wen Li; Nannan Fan; Xin Ma
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2015-05

10.  Treatment of ulcerative colitis using fecal bacteriotherapy.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn Leis; Rosa Surace; Ori Ashman
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

View more
  12 in total

Review 1.  Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.

Authors:  Ryan Eliott; Pratik Panchal; Shrish Budree; Alex Scheeler; Geraldine Medina; Monica Seng; Wing Fei Wong; Thomas Mitchell; Zain Kassam; Jessica R Allegretti; Majdi Osman
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

2.  European consensus conference on faecal microbiota transplantation in clinical practice.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Herbert Tilg; Mirjana Rajilić-Stojanović; Patrizia Kump; Reetta Satokari; Harry Sokol; Perttu Arkkila; Cristina Pintus; Ailsa Hart; Jonathan Segal; Marina Aloi; Luca Masucci; Antonio Molinaro; Franco Scaldaferri; Giovanni Gasbarrini; Antonio Lopez-Sanroman; Alexander Link; Pieter de Groot; Willem M de Vos; Christoph Högenauer; Peter Malfertheiner; Eero Mattila; Tomica Milosavljević; Max Nieuwdorp; Maurizio Sanguinetti; Magnus Simren; Antonio Gasbarrini
Journal:  Gut       Date:  2017-01-13       Impact factor: 23.059

Review 3.  New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Mingxia Zhou; Jing He; Yujie Shen; Cong Zhang; Jiazheng Wang; Yingwei Chen
Journal:  Biomed Res Int       Date:  2017-08-02       Impact factor: 3.411

4.  The recognition and attitudes of postgraduate medical students toward fecal microbiota transplantation: a questionnaire study.

Authors:  Xia Wu; Min Dai; Heena Buch; Jianling Bai; Wenwu Long; Chuyan Long; Xianyan Tang; Hua Tu; Renjie Zhang; Cairong Zhu; Shaoqi Yang; Bota Cui; Guozhong Ji; Faming Zhang
Journal:  Therap Adv Gastroenterol       Date:  2019-09-02       Impact factor: 4.409

5.  Medical students' perception on fecal microbiota transplantation.

Authors:  Petru C Madar; Oana Petre; Adriana Baban; Dan L Dumitrascu
Journal:  BMC Med Educ       Date:  2019-10-11       Impact factor: 2.463

6.  Patients and physicians' attitudes change on fecal microbiota transplantation for inflammatory bowel disease over the past 3 years.

Authors:  Yujie Zhang; Xianmin Xue; Song Su; He Zhou; Yirong Jin; Yanting Shi; Junchao Lin; Jiayao Wang; Xiaofei Li; Gang Yang; Jessica R Philpott; Jie Liang
Journal:  Ann Transl Med       Date:  2021-11

Review 7.  Healthcare providers' perception of faecal microbiota transplantation with clostridium difficile infection and inflammatory bowel disease: a quantitative systematic review.

Authors:  Yanghua Liu; Kal Alnababtah; Simon Cook; Ying Yu
Journal:  Therap Adv Gastroenterol       Date:  2021-09-20       Impact factor: 4.409

Review 8.  Microbiota transplantation: concept, methodology and strategy for its modernization.

Authors:  Faming Zhang; Bota Cui; Xingxiang He; Yuqiang Nie; Kaichun Wu; Daiming Fan
Journal:  Protein Cell       Date:  2018-04-24       Impact factor: 14.870

9.  Awareness and attitude of fecal microbiota transplantation through transendoscopic enteral tubing among inflammatory bowel disease patients.

Authors:  Min Zhong; Yang Sun; Hong-Gang Wang; Cicilia Marcella; Bo-Ta Cui; Ying-Lei Miao; Fa-Ming Zhang
Journal:  World J Clin Cases       Date:  2020-09-06       Impact factor: 1.337

10.  Fecal microbiota transplantation: Current status and challenges in China.

Authors:  Yi-Chao Shi; Yun-Sheng Yang
Journal:  JGH Open       Date:  2018-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.